Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07420998

Effect of a Nutritional Product Containing Carob Extract on Carbohydrate Metabolism in Glucose-intolerant Subjects

Randomized, controlled, double-blind clinical trial with two parallel arms based on the product consumed (experimental product and placebo product) and conducted at a single center, to measure the efficacy of the liquid NUTIFOOD product (nutritional product with carob extract) on carbohydrate metabolism.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCAM HiTech, Sport & Health Innovation Hub

Murcia, Spain

Location status: Recruiting

Location contact

Francisco Javier López Román

CONTACT

[email protected]

968278157 ext. 157

About this study

This study evaluates the effects of NUTIFOOD (liquid nutritional product with carob extract) on insulin sensitivity and carbohydrate metabolism in subjects with abnormal glucose or HbA1c levels not on antidiabetic medication, over 90 days.

Key assessments include: Glucose response (AUC and peak levels) during an oral glucose tolerance test. Changes in fasting glucose, HbA1c, and basal insulin. Insulin resistance measured by HOMA-IR and QUICKI. Effects on body composition. Safety and tolerability of the product.

The study aims to determine the potential of NUTIFOOD as a nutritional intervention to improve glucose regulation and metabolic health.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects of both sexes aged 18-65 years.
  • Diagnosis of glucose intolerance according to the American Diabetes Association (at least one of the following criteria):
  • Impaired fasting glucose (100-125 mg/dl)
  • Impaired glucose tolerance (oral glucose tolerance test with 2-hour plasma glucose between 140-199 mg/dl)
  • Glycated hemoglobin between 5.7% and 6.4%
  • Body mass index between 20-35 kg/m².
  • Stable dietary habits: no weight gain or loss greater than 5 kg in the last ten weeks.
  • Volunteers capable of understanding the clinical study and willing to comply with the study procedures and requirements.

Exclusion criteria

  • Use of medications that may interfere with glucose metabolism.
  • Subjects with a history of any type of hepatic or renal disease.
  • Alcohol consumption greater than 20 g/day.
  • History of allergic hypersensitivity or poor tolerance to any component of the study products.
  • Participation in another clinical trial within the three months prior to the study.
  • Lack of willingness or inability to comply with clinical trial procedures.
  • Pregnant or breastfeeding women.

Treatment and study plan

Experimental product

Dietary Supplement

Participants will consume two doses per day. The product should be taken 30 minutes before the two main meals of the day.

Other names: Carob liquid - GippsNature

Control product

Dietary Supplement

Participants will consume two daily doses of the placebo product. The product should be taken 30 minutes before the two main meals of the day.

Other names: Placebo

Primary outcomes

  1. Glycated Hemoglobin (HbA1c)

    Time frame: Measurements will be performed at baseline, Day 45, and Day 90

    Fasting glycated hemoglobin (HbA1c) will be measured in venous blood samples to assess long-term glycemic control.

  2. Area Under the Curve (AUC) of Blood Glucose During Oral Glucose Tolerance Test

    Time frame: This assessment will be conducted at baseline, Day 45, and Day 90.

    The area under the curve (AUC) of blood glucose will be calculated during an oral glucose tolerance test (OGTT) using a 50-g glucose load. Capillary blood glucose levels will be measured at 0, 15, 30, 45, 60, 90, and 120 minutes after glucose ingestion.

Secondary outcomes

  1. Fasting and Post-Load Insulinemia

    Time frame: These measurements will be performed at baseline, Day 45, and Day 90.

    Fasting venous insulin levels will be measured at baseline. Post-load venous insulin concentrations will be determined at 45 and 90 minutes during the oral glucose tolerance test (50-g glucose load).

  2. Insulin Resistance

    Time frame: They will be calculated at the start of the study, on day 45, and on day 90.

    Peripheral insulin resistance will be assessed using validated surrogate indices derived from fasting glucose and insulin levels: HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)

  3. Insulin Sensitivity

    Time frame: It will be calculated at the start of the study, on day 45, and on day 90.

    Insulin sensitivity will be assessed using validated surrogate indices derived from fasting glucose and insulin levels: QUICKI (Quantitative Insulin Sensitivity Check Index).

  4. Body Composition Analysis

    Time frame: These measurements will be performed at baseline, Day 45, and Day 90.

    Body composition will be assessed using bioelectrical impedance analysis (BIA), providing estimates of fat mass, lean mass, and total body water.

  5. Liver safety variables

    Time frame: These measurements will be performed at baseline, on day 45, and on day 90.

    It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L)

  6. Adverse events

    Time frame: At 12 weeks after consumption

    It will be evaluated at each of the visits.

Study contacts

Contact information is provided by the study sponsor or research team.

Francisco Javier López Román

CONTACT

[email protected]

968278157 ext. 157

Sponsors and collaborators

Lead sponsor

Universidad Católica San Antonio de Murcia

Other

Registry information

Official study title

Randomized Clinical Trial on the Effect of a Nutritional Product Containing Carob Extract (NUTIFOOD) on Carbohydrate Metabolism in Glucose-intolerant Subjects

Acronym: NUTIFOOD

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 19, 2026
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.